Announcement on the Voluntary Information Disclosure Regarding the Launch of Phase II Clinical Trial for RSV Vaccine by Naimixin (Shanghai) Biotechnology Co., Ltd.

Chengdu Kanghua Biological Products Co., Ltd.·May 29, 2026·3 pages

✨ AI Summary

Chengdu Kanghua Biological Products Co., Ltd. announces the initiation of a Phase II clinical trial for the RSV vaccine developed by Naimixin (Shanghai) Biotechnology Co., Ltd. The trial aims to evaluate the immunogenicity and safety of the vaccine in individuals aged 60 and above. The company is in the process of acquiring 100% ownership of Naimixin, with the first phase of the investment currently underway.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Chengdu Kanghua Biological Products Co., Ltd. (hereinafter referred to as "the Company") intends to acquire Naimixin (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Naimixin"), which has officially launched the Phase II clinical trial for its self-developed freeze-dried respiratory syncytial virus mRNA vaccine (hereinafter referred to as "RSV vaccine"). The relevant information is announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.